M&A Deal Summary |
|
|---|---|
| Date | 2015-08-19 |
| Target | Rare Pediatric Disease Priority Review Voucher |
| Sector | Life Science |
| Buyer(s) | AbbVie |
| Sellers(s) | United Therapeutics |
| Deal Type | Divestiture |
| Deal Value | 350M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 50,000 |
| Revenue | 54.3B USD (2023) |
AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 12 |
| Sector (Life Science) | 2 of 12 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 2 of 10 |
| Year (2015) | 2 of 2 |
| Size (of disclosed) | 8 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-03-04 |
Pharmacyclics
Sunnyvale, California, United States Pharmacyclics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. |
Buy | $21.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-04-28 |
Stemcentrx
South San Francisco, California, United States Stemcentrx develops therapies that aim to cure and significantly improve survival for cancer patients. The Company was formed in 2008 and is based South San Francisco, California. |
Buy | $5.8B |
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Medical Products |
| Employees | 950 |
| Revenue | 2.3B USD (2023) |
United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics was founded in 1996 and is based in Silver Spring, Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2015) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2000-12-01 |
Cooke Pharma
Silver Spring, Maryland, United States Cooke Pharma, Inc. is a technology platform based on the use of L-arginine, an essential amino acid that has demonstrated efficacy in increasing blood flow. The company applied its technology to consumer applications addressing coronary heart disease, creating The Heart Bar, a medical food designed to treat the symptoms of coronary heart disease (CHD) and peripheral artery disease (PAD). |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-08-30 |
SteadyMed
San Ramon, California, United States SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development-stage drug-device combination product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat PAH. SteadyMed has signed an exclusive license and supply agreement with Cardiome Pharma Corp. |
Buy | $216M |
